These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 3394654

  • 1. In vivo inhibition of foam cell development by probucol in Watanabe rabbits.
    Steinberg D, Parthasarathy S, Carew TE.
    Am J Cardiol; 1988 Jul 25; 62(3):6B-12B. PubMed ID: 3394654
    [Abstract] [Full Text] [Related]

  • 2. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit.
    Carew TE, Schwenke DC, Steinberg D.
    Proc Natl Acad Sci U S A; 1987 Nov 25; 84(21):7725-9. PubMed ID: 3478721
    [Abstract] [Full Text] [Related]

  • 3. Prevention of atherosclerotic progression in Watanabe rabbits by probucol.
    Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Narumiya S, Kawai C.
    Am J Cardiol; 1988 Jul 25; 62(3):13B-19B. PubMed ID: 3394648
    [Abstract] [Full Text] [Related]

  • 4. Probucol does not affect lipoprotein metabolism in macrophages of Watanabe heritable hyperlipidemic rabbits.
    Nagano Y, Kita T, Yokode M, Ishii K, Kume N, Otani H, Arai H, Kawai C.
    Arteriosclerosis; 1989 Jul 25; 9(4):453-61. PubMed ID: 2751475
    [Abstract] [Full Text] [Related]

  • 5. The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters.
    El-Swefy S, Schaefer EJ, Seman LJ, van Dongen D, Sevanian A, Smith DE, Ordovas JM, El-Sweidy M, Meydani M.
    Atherosclerosis; 2000 Apr 25; 149(2):277-86. PubMed ID: 10729377
    [Abstract] [Full Text] [Related]

  • 6. Probucol treatment affects the cellular composition but not anti-oxidized low density lipoprotein immunoreactivity of plaques from Watanabe heritable hyperlipidemic rabbits.
    O'Brien K, Nagano Y, Gown A, Kita T, Chait A.
    Arterioscler Thromb; 1991 Apr 25; 11(3):751-9. PubMed ID: 2029510
    [Abstract] [Full Text] [Related]

  • 7. Probucol selectively increases oxidation of atherogenic lipoproteins in cholesterol-fed mice and in Watanabe heritable hyperlipidemic rabbits.
    Lauridsen ST, Mortensen A.
    Atherosclerosis; 1999 Jan 25; 142(1):169-78. PubMed ID: 9920518
    [Abstract] [Full Text] [Related]

  • 8. The role of oxidized low density lipoprotein in the pathogenesis of atherosclerosis.
    Kita T, Ishii K, Yokode M, Kume N, Nagano Y, Arai H, Kawai C.
    Eur Heart J; 1990 Aug 25; 11 Suppl E():122-7. PubMed ID: 2226520
    [Abstract] [Full Text] [Related]

  • 9. Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions.
    Yamamoto A, Hara H, Takaichi S, Wakasugi J, Tomikawa M.
    Am J Cardiol; 1988 Jul 25; 62(3):31B-36B. PubMed ID: 3394651
    [Abstract] [Full Text] [Related]

  • 10. Role of biologically modified low-density lipoprotein in atherosclerosis.
    Carew TE.
    Am J Cardiol; 1989 Oct 03; 64(13):18G-22G. PubMed ID: 2679026
    [Abstract] [Full Text] [Related]

  • 11. Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
    Kleinveld HA, Demacker PN, Stalenhoef AF.
    Arterioscler Thromb; 1994 Aug 03; 14(8):1386-91. PubMed ID: 8049202
    [Abstract] [Full Text] [Related]

  • 12. [Prevention of atherosclerosis using an antioxidant].
    Ishii K, Kita T.
    Nihon Ronen Igakkai Zasshi; 1990 Mar 03; 27(2):177-81. PubMed ID: 2384991
    [Abstract] [Full Text] [Related]

  • 13. Probucol treatment attenuates the aortic atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
    Oshima R, Ikeda T, Watanabe K, Itakura H, Sugiyama N.
    Atherosclerosis; 1998 Mar 03; 137(1):13-22. PubMed ID: 9568732
    [Abstract] [Full Text] [Related]

  • 14. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.
    Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C.
    Proc Natl Acad Sci U S A; 1987 Aug 03; 84(16):5928-31. PubMed ID: 3475709
    [Abstract] [Full Text] [Related]

  • 15. Studies on the mechanism of action of probucol.
    Steinberg D.
    Am J Cardiol; 1986 Jun 27; 57(16):16H-21H. PubMed ID: 3728306
    [Abstract] [Full Text] [Related]

  • 16. The role of oxidized lipoproteins in the pathogenesis of atherosclerosis.
    Kita T, Yokode M, Ishii K, Kume N, Nagano Y, Arai H, Otani H, Ueda Y, Hara S.
    Clin Exp Pharmacol Physiol Suppl; 1992 Jun 27; 20():37-42. PubMed ID: 1446408
    [Abstract] [Full Text] [Related]

  • 17. Probucol inhibits oxidative modification of low density lipoprotein.
    Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D.
    J Clin Invest; 1986 Feb 27; 77(2):641-4. PubMed ID: 3944273
    [Abstract] [Full Text] [Related]

  • 18. Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits.
    Witting P, Pettersson K, Ostlund-Lindqvist AM, Westerlund C, Wâgberg M, Stocker R.
    J Clin Invest; 1999 Jul 27; 104(2):213-20. PubMed ID: 10411551
    [Abstract] [Full Text] [Related]

  • 19. The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits.
    Daugherty A, Zweifel BS, Schonfeld G.
    Br J Pharmacol; 1991 May 27; 103(1):1013-8. PubMed ID: 1878742
    [Abstract] [Full Text] [Related]

  • 20. Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.
    Mao SJ, Yates MT, Rechtin AE, Jackson RL, Van Sickle WA.
    J Med Chem; 1991 Jan 27; 34(1):298-302. PubMed ID: 1992130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.